Dividend investors started the year with fresh signals of continued shareholder returns, with three long-established companies—PepsiCo, 3M, and Gilead Sciences—announcing higher quarterly payouts in early February. While none of the announcements were tied to earnings reports or major forecast changes in the text provided, each company’s increase—and the fundamentals behind it—offers a timely check on how cash flows are holding up heading into 2022.
Key takeaways
- PepsiCo raised its quarterly dividend to just under $1.08 per share, a 5% increase, supporting a dividend streak spanning 50 years.
- 3M lifted its quarterly dividend by 0.6% to $1.49 per share amid expectations that 2022 growth will slow.
- Gilead Sciences increased its quarterly payout by nearly 3% to $0.73 per share, with the dividend tied to an indicated 4.8% yield at current pricing cited in the article.
- Implication: Even modest hikes reinforce long-term capital return frameworks, but near-term momentum varies by company—especially as pandemic-related demand normalizes and legal costs weigh.
What PepsiCo announced and why it matters
PepsiCo increased its quarterly dividend in early February, setting the next payout at just under $1.08 per share, representing a 5% year-over-year raise. The company also emphasized durability: the move marks the 50th consecutive year of dividend increases, a milestone that positions PepsiCo among the relatively rare “Dividend Kings” in the market.
Underpinning the payout is the company’s recent operating performance. According to the article, PepsiCo reported net revenue of more than $25 billion for 2021, up nearly 13% year over year, supported by roughly equal gains across both drinks and snacks. Adjusted net profit rose about 13% as well, to nearly $8.7 billion. The article suggests that elevated demand during the pandemic—such as higher home-consumption of packaged foods and beverages—helped drive the gains.
Investors will receive the raised dividend on March 31 if they are stockholders of record as of March 4. Based on the most recent closing share price cited in the article, the increase implies a yield slightly under 2.6%.
3M’s small raise amid a slower growth outlook
3M also began the year with a dividend increase. The quarterly distribution was raised by 0.6% to $1.49 per share, extending the company’s streak to 64 straight years of dividend increases.
The article links the modest size of the hike to how 3M has navigated pandemic-era disruptions. It notes that 2021 was challenging for the industrial conglomerate due to persistent supply constraints tied to the pandemic. Still, it says 3M’s positioning across multiple industrial segments, combined with changes to its corporate structure and a series of divestments and asset purchases, helped sustain performance.
According to the article, 3M reported that all businesses performed better than internal expectations in the fourth quarter, and that full-year sales increased by nearly 10% versus 2020. It also cites an even stronger improvement in annual net profit, up about 15%.
Looking ahead, 3M’s near-term path may be less smooth. The article points to a mid-February business update indicating that falling demand for face masks—products tied to pandemic needs—would affect results. It also states that annual growth is expected to slow to about 4% in 2022, while anticipated net profit remains within analyst expectations.
For shareholders, the raised dividend is scheduled for March 12, payable to investors of record as of Feb. 18. The article estimates a yield of almost 3.8% at the cited recent share price.
Gilead’s dividend increase as COVID treatment demand fades
Gilead Sciences declared a dividend raise in early February, increasing its quarterly payout by nearly 3% to $0.73 per share. The article frames this move against a backdrop of shifting demand for the company’s COVID-19 therapy and other cost pressures.
Gilead is identified in the article as the developer behind Veklury (remdesivir), which received FDA approval in late 2020. However, it says the drug did not become the breakout success some expected, citing skepticism among medical professionals regarding effectiveness and a broader policy shift toward vaccines rather than cure-driven treatment.
The article attributes part of the company’s performance pressure to the decline in Veklury popularity. It states that Q4 revenue fell 2% year over year to $7.2 billion. It also notes that Gilead entered into a $1.25 billion legal settlement with GlaxoSmithKline related to HIV drug patents—an additional factor weighing on results.
Despite those challenges, the article argues Gilead still has commercial strengths, including Biktarvy as a leading HIV therapy and a pipeline under development, particularly in oncology. The dividend increase adds another layer of shareholder return: the article says the new payout will be distributed on March 30 to shareholders of record as of March 15, and that it equates to a 4.8% yield at the current share price cited.
Bigger picture: what dividend hikes suggest going into 2022
Taken together, the three announcements reinforce how dividend-focused investors are still finding support in large-cap cash generators—even as the market digests the transition away from pandemic-driven demand and evaluates the durability of corporate earnings power. PepsiCo’s larger percentage increase aligns with stronger recent top- and bottom-line growth cited in the article, while 3M’s smaller raise reflects a more cautious growth outlook. Gilead’s hike, meanwhile, underscores that payout policy remains active even when revenue trends are being pressured by product demand shifts and legal costs.
For investors, the next key signals will likely come from each company’s subsequent earnings updates and any guidance changes—particularly as the market assesses how much of the earlier demand surge is fading, whether legal and product-related headwinds persist, and how comfortably free cash flow can sustain dividend growth through 2022.
